GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (NAS:FTRE) » Definitions » Altman Z2-Score

Fortrea Holdings (Fortrea Holdings) Altman Z2-Score : 1.13 (As of May. 23, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Fortrea Holdings Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Fortrea Holdings has a Altman Z2-Score of 1.13, indicating it is in Grey Zones. This implies that Fortrea Holdings is in some kind of financial stress. If it is below 1.1, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Fortrea Holdings's Altman Z2-Score or its related term are showing as below:

FTRE' s Altman Z2-Score Range Over the Past 10 Years
Min: 1.13   Med: 1.64   Max: 4.92
Current: 1.13

During the past 4 years, Fortrea Holdings's highest Altman Z2-Score was 4.92. The lowest was 1.13. And the median was 1.64.


Fortrea Holdings Altman Z2-Score Historical Data

The historical data trend for Fortrea Holdings's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortrea Holdings Altman Z2-Score Chart

Fortrea Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Altman Z2-Score
- - 4.92 1.48

Fortrea Holdings Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.99 1.69 1.58 1.48 1.13

Competitive Comparison of Fortrea Holdings's Altman Z2-Score

For the Biotechnology subindustry, Fortrea Holdings's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortrea Holdings's Altman Z2-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortrea Holdings's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Fortrea Holdings's Altman Z2-Score falls into.



Fortrea Holdings Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Fortrea Holdings's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.0908+3.26*-0.0354+6.72*0.0016+1.05*0.6049
=1.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2024:
Total Assets was $4,251 Mil.
Total Current Assets was $1,205 Mil.
Total Current Liabilities was $819 Mil.
Retained Earnings was $-151 Mil.
Pre-Tax Income was -77.5 + -41 + -17.9 + 38.9 = $-98 Mil.
Interest Expense was -34.3 + -34.5 + -34.6 + -0.7 = $-104 Mil.
Total Liabilities was $2,649 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(1204.5 - 818.6)/4250.7
=0.0908

X2=Retained Earnings/Total Assets
=-150.5/4250.7
=-0.0354

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-97.5 - -104.1)/4250.7
=0.0016

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(1602.1 - 0)/2648.6
=0.6049

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Fortrea Holdings has a Altman Z2-Score of 1.13 indicating it is in Grey Zones.


Fortrea Holdings  (NAS:FTRE) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Fortrea Holdings Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Fortrea Holdings's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortrea Holdings (Fortrea Holdings) Business Description

Traded in Other Exchanges
Address
8 Moore Drive, Durham, NC, USA, 27709
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Executives
Thomas Pike officer: Chief Executive Officer C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601
Peter M Neupert director 13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005
Betty D Larson director GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE, CHICAGO IL 60661
R Andrew Eckert director THREE RAVINIA DRIVE, ATLANTA GA 30346
Edward A Pesicka director 9120 LOCKWOOD BLVD, MECHANICSVILLE VA 23116
Amrit Ray director 60 LEVERONI COURT, NOVATO CA 94949
Amanda M. Warren officer: Chief Accounting Officer 8 MOORE DRIVE, DURHAM NC 27703
David Ross Smith director 251 BALLARDVALE STREET, WILMINGTON MA 01887
Van Der Vaart Sandra D director, officer: President and Secretary 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg director, officer: Executive Vice President P O BOX 1017, CHARLOTTE NC 28201-1017
James S. Hanson officer: General Counsel 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Laboratory Corp Of America Holdings 10 percent owner 358 S MAIN ST, BURLINGTON NC 27215
Jill G. Mcconnell officer: Chief Financial Officer 8 MOORE DRIVE, DURHAM NC 27703
Mark A. Morais officer: Chief Operating Officer 8 MOORE DRIVE, DURHAM NC 27703
Robert S. Pringle officer: Treasurer 531 SOUTH SPRING STREET, BURLINGTON NC 27215